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Abstract










Bortezomib (Velcade) is a first-in-class proteasome inhibitor developed specifically for use as an anti-neoplastic agent. It is the most potent anti-neoplastic agent for the treatment of relapsed, refractory multiple myeloma.1 73% of patients with myeloma responded to treatment with Bortezomib combined with pegylated liposomal doxorubicin.2 However, only 4 of 15 patients with acute leukaemia showed a decrease in blast count.3 
The efficacy of Bortezomib in chronic lymphocytic leukaemia (CLL) appears to be related to IgV(H) and BCL-6 mutational status,4 down-regulation of CD23 and inactivation of Notch 2.5 However, we have previously shown that all primary CLL cells were sensitive to Bortezomib in vitro. Proteasome inhibition increased Bax protein accumulation and Bax activation in CLL cells. Bortezomib also increased the sensitivity of CLL cells to TRAIL-induced apoptosis.6 Although the effectiveness of Bortezomib killing of CLL cells in vitro has also been reported by other groups,4,5  it did not display substantial anti-tumor activity in patients with CLL.7,8 The basis of this differential activity of Bortezomib on CLL cells in vivo and in vitro is unknown. Autologous plasma is capable of maintaining survival of CLL cells in vitro and conferring resistance to chemo-radiotherapy9 and albumin in plasma plays an important role in this survival mechanism.10  We sought to identify factors in the blood, which could prevent Bortezomib-mediated killing of leukemic cells in the circulation. 
Quercetin is one of the most abundant flavonoids in the human diet and is a potent anti-oxidant.11 Quercetin, abundant in human plasma, covalently binds to serum albumin.12,13 It contributes to the prevention of human diseases by promoting relaxation of cardiovascular smooth muscle and protects low-density lipoprotein from oxidation.14 Recent studies found that quercetin can induce apoptosis by inhibiting proteasome activation,15 causing G2/M phase arrest16 and increasing p21 expression.17 Other dietary flavonoids, such as myricetin, kaempferol and apigenin, also have similar functions to quercetin with respect to proteasome inhibition and apoptosis induction.15
In this study, we demonstrate that human plasma affects killing by Bortezomib and that the dietary flavonoids, especially quercetin, inhibit Bortezomib-induced apoptosis in malignant B-cell lines and primary CLL cells. This inhibitory activity of quercetin was associated with complex formation with Bortezomib. However, in myeloma cell lines, quercetin also had an additional direct effect on the cells to increase their sensitivity to Bortezomib. Overall, dietary flavonoids show competing interactions with tumor cells and Bortezomib, which are dose- and tumor type dependent. 
Materials and Methods
Materials
Bortezomib was provided by Millennium Pharmaceuticals as the boronate ester with D-mannitol (Cambridge, MA). Human albumin solution 20% was from Baxter (Norfolk, UK). MG-132 and Ac-IETD-AFC were obtained from Biomol International (Exeter, UK). Quercetin, myricetin, apigenin, kaempferol, lactacystin, propidium iodide (PI), DAPI, the monoclonal anti--actin antibody, Ac- LEHD-AFC, 7-amino-4-trifluoromethylcoumarin (AFC), N-acetyl-L-cysteine (NAC), boric acid and all other chemicals were purchased from Sigma (Poole, Dorset UK). Ac-DEVD-AFC and MG-262 were purchased from Calbiochem (Nottingham, UK). Annexin V-FITC kit, anti-cytochrome c clone 6H2.B4 antibody, anti-Bax (6A7) monoclonal antibody and anti-Bax antibody clone 3 were purchased from BD Biosciences (San Diego, CA). The monoclonal anti-Bax 2D2 antibody (clone YTH-2D2) was purchased from R & D Systems (Oxon, UK). MitoTrackerTM red CMXRos, Tetramethylrhodamine, methyl ester (TMRM), dihydroethidium (HE), 2’,7’-dichlorodihydrofluorescein diacetate (H2-DCFDA), and M-450 Rat anti-Mouse IgG1 Dynabeads were from Invitrogen (Carlsbad, CA). 
Cell culture
The EBV transformed human B cell line, HRC57 (provided by Cancer Research UK cancer cell services), and the human diffuse large B cell lymphoma (DLBCL) cell line, DoHH2, the human myeloma cell lines, RPMI-8226 and U266, were used in this study. Cells were cultured in RPMI 1640 medium (Sigma) supplemented with 10% heat-inactivated fetal calf serum (FCS), 25 mM HEPES, 2.0 mM L-glutamine, pH 7.4, penicillin (100 U/ml), streptomycin (100 g/ml) at 37°C in a 5% CO2 humidified incubator. Peripheral blood was obtained after written informed consent from patients with CLL. The mononuclear cells were isolated by density centrifugation over Ficoll. 
Apoptosis assays
 Apoptosis was determined by both Annexin V and DNA content assays. The Annexin V assay was performed according to the protocol of the Annexin V-FITC kit. Whole cells in the binding buffer suspension were stained with 5 l of Annexin V-FITC and 10 l of PI for 15 minutes at the room temperature in the dark. Annexin V-FITC and PI fluorescence were measured by flow cytometry (Becton Dickinson FACScan) on the FL1-H and FL3-H channels, respectively.  Annexin V positive cells (both PI negative and positive) were defined as apoptotic. DNA content was measured by flow cytometry. Briefly, cells were permeabilized in 70% ethanol for 40 minutes at 4°C. After washing twice with PBS, cells were incubated at 37°C with 25 g/ml RNase A and 50 g/ml PI for 1 hour. PI fluorescence of nuclei was measured by flow cytometry. Data analysis was carried out on cells gated on an FL2-Area channel versus FL2-Width channel display to exclude cell debris and clumped cells. DNA content distribution (PI fluorescence) was analyzed on the FL2-Area histogram and cells with a DNA content less than G0/G1 (hypodiploid) were defined as apoptotic cells. 18 
Fluorogenic assay for quercetin-albumin binding
The fluorescence elicited by albumin/quercetin interactions was determined in black microtiter plates (Nunc) at a wavelength of 528±20 nm with an excitation wavelength at 485±20 nm using a Bio-Tek SynergyTM HT Multi-Detection Microplate Reader (Vermont, USA). The human serum albumin (Baxter) concentration was fixed at 25 M (0.167%, w/v) and quercetin concentration varied between 2 to 20 M.19 Quercetin and albumin were added to PBS up to 100 l total volume and incubated for 10 minutes at the room temperature. 
Caspase activity assay
Cells were lysed and proteins (50 g) were diluted with fluorogenic assay buffer (20 mM PIPES-KOH, pH 7.4; 10 mM DTT, 10% sucrose, 1.0 mM EDTA, and 0.1% CHAPS) to 90 l. The reaction was initiated by the addition of 5 l of 400 M (final concentration was 20 M) fluorescent substrate, Ac-DEVD-AFC for caspase-3, Ac-IETD-AFC for caspase-8, or Ac-LEHD-AFC for caspase-9. After incubation at 37C for 15 minutes, the reaction was stopped by the addition of 50 l of 1% sodium acetate trihydrate in 175 mM acetic acid and cooling on ice.18 The fluorescence at 400/505 nm for AFC release by the caspase cleavage was measured using a Bio-Tek SynergyTM HT Multi-Detection Microplate Reader (Vermont, USA). Measurements were calibrated against a standard linear regression curve of AFC. Caspase activity was defined as M AFC release per mg protein per minute (M/hr/mg protein).
Measurement of mitochondrial membrane potential (m) and reactive oxidative species (ROS) by flow cytometry
To measure m, cells were stained with 20 nM TMRM for 30 minutes at 37C. The fluorescent intensities were measured in the FL3-H channel with flow cytometer. The intracellular accumulation of ROS was determined using the fluorescent probe HE to measure O2 at FL3-H and H2-DCFDA for H2O2 at FL1-H.  After the treatment, cells (105/ml) were incubated with 40 M HE and 5 M H2-DCFDA for 15 minutes at 37C. ROS generation was then assessed by flow cytometry. 20 
Immuno-staining of Bax translocation and cytochrome c release
After treatment with Bortezomib with or without quercetin, the intact cells were first labeled with the mitochondrion-specific dye, MitoTrackerTM red CMXRos. Cells in culture medium were incubated with MitoTrackerTM (100 nM) at 37C for 15 minutes. After washing, cells were fixed/permeabilized on slides. To detect Bax translocation, cells on the slides were incubated with the anti-Bax antibody clone 3 at 1:50 dilution for 1 hour.  To determine cytochrome c release from mitochondria, cells on the slides were incubated with the anti-cytochrome c antibody 6H2.B4 (1:400 dilution) for 2 hours. They were then incubated with FITC-conjugated anti-mouse secondary antibody (Sigma) at a 1:20 dilution. Slides were washed with PBS, air dried at 4C in the dark and stained with DAPI before viewing under a Zeiss Axioskop fluorescence microscope (Zeiss, Germany).18,21,22
Immuno-precipitation and Western blotting
Cells were washed with PBS and lysed with Chaps buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 1% Chaps, 1 mM DTT, 0.1 mM PMSF, 3 g/ml aprotinin, 25 g/ml leupeptin, and 25 g/ml pepstain). 1 g of anti-Bax (6A7) monoclonal antibody was pre-incubated with 20 l of Dynabeads (M-450 Rat anti-Mouse IgG1) at 4°C on the rotor for 3 hours. The cell lysates were normalized for protein content and 1000 g of total protein in 300 l Chaps lysis buffer were then added to the immuno-precipitation tube containing Bax antibody (6A7)-loaded Dynabeads and incubated at 4°C on the rotor overnight. After rinsing 4 times with Chaps buffer, beads were collected with a Dynal Magnetic Particle Concentrator.  Conformationally changed Bax protein was eluted with 25 l of sample buffer for Western blotting by the monoclonal anti-Bax antibody, clone 2D2.6,23 
Raman spectroscopy for determining chemical reactions between quercetin and Bortezomib, MG-262, or boric acid
Raman spectra of the samples were recorded using a Raman spectrometer, Almega (Thermo Fisher Scientific, Madison Wisconsin, USA). The laser used in this study, is a 785nm Near Infrared (NIR) High Power Diode laser, with a laser power of 300mW, Multimode Continuous Wave beam, and Power Stability of < 5%.  The laser power can be changed from 15 to 100%, according to the requirements of experiments and in this study a laser power of 100mW was used for the analysis. The spectrometer has a CCD Detector of Andor DV420 Open Electrode, with a working temperature of -50oC. In this experiment, all of the spectra were collected in quartz tubes within the range of 100-3430cm-1, using a pinhole of 100 µm.  A total of 256 exposures with exposure time of 2.00 seconds (for each exposure) were used to obtain a spectrum.
Results
Human plasma counteracts the apoptosis-inducing effect of Bortezomib in CLL cells. 
The pro-apoptotic activity of Bortezomib on fresh primary CLL cells was tested in both routine culture medium and 50% autologous plasma. CLL cells in the culture medium were sensitive to 20 nM Bortezomib-induced apoptosis (Figure 1 A).  However, the pro-apoptotic activity of Bortezomib was significantly inhibited when CLL cells were cultured in 50% fresh autologous plasma (Figure 1 B). Human serum albumin (HSA) is the most abundant protein in the plasma with a reference range of 3-5% in the blood. However, HSA, at concentrations between 1-5%, did not block 20 nM Bortezomib-induced apoptosis in the DoHH2 cell line (Figure 1 C). Quercetin is the main dietary flavonoid in blood, with anti-oxidative and proteasome inhibition activities, but can itself induce apoptosis in leukemic Jurkat T-cells.15 It shows strong binding to purified albumin19 producing a dose-dependent fluorescence (Figure 1 D).  The peak concentration of quercetin in the serum is 0.8 M after the onion meal for 25 hours.24 Therefore, the quercetin concentration in the purified and stored albumin is negligible.  [Li – I do NOT think we need to add this additional text; only one reviewer asked about this and the response is in the letter of reply, but it does not fit in here.] Quercetin, at 20 M, completely inhibited 20 nM Bortezomib-induced apoptosis and binding to HSA did not diminish its inhibitory effect (Figure 1 C).  
Quercetin blocks Bortezomib-induced apoptosis in malignant B-cells.  
We sought to determine the role of quercetin in Bortezomib-induced apoptosis in both CLL and the malignant B-cell lines. Cells were pre-treated with 20 to 60 µM quercetin for 1 hour and then incubated with or without 20 nM Bortezomib for 16 hours. Apoptotic cells were measured by the DNA content assay using a flow cytometer. Figure 2 A is an example showing the dose-dependent inhibitory effect of quercetin on Bortezomib-induced apoptosis in primary CLL cells. Quercetin induced apoptosis when the concentration was higher than 20 M, as shown by the increased sub-G0/G1 cell populations. Interestingly, Bortezomib-induced apoptosis was completely inhibited by 20 M quercetin (Figure 2 A). Similar results were seen in both the EBV transformed HRC57 cell line and the DLBCL DoHH2 cell line (Figure 2 B).  Quercetin also had the same inhibitory effect on Bortezomib-induced apoptosis in two myeloma cell lines, U266 and RPMI-8226 (Figure 2 B). However, the myeloma cell lines required higher levels of quercetin (40 M) for maximal inhibition of Bortezomib-induced apoptosis, as compared to 20 M for primary CLL, HRC57 and DoHH2 cells. In addition, myeloma cell lines were more susceptible to quercetin-mediated G2/M arrested compared with the B-lymphoma cell lines (data not shown). 
The effect of adding quercetin 20 M (at which concentration it was not apoptotic to cells) one hour before, or simultaneously with, Bortezomib is shown in Figure 2C. Bortezomib-induced apoptosis showed a dose-response in all four cell lines studied, with significant apoptosis seen at the lowest dose tested (10 nM). Quercetin significantly (P<0.0001, ANOVA) blocked Bortezomib-induced apoptosis in all four cell lines when both compounds were added simultaneously. When quercetin was added for one hour prior to the addition of Bortezomib, the same inhibitory effect on Bortezomib-induced killing was seen in HRC57 and DoHH2. However, in both myeloma cells lines, pre-incubation with quercetin showed led to less resistance toinhibition of Bortezomib-induced killing, suggesting that myeloma cells are more active in their inuptake and utilization ofing quercetin, thereby and reducinge the chemical binding between quercetin and Bortezomib.  
Quercetin inhibits Bortezomib-induced Bax activation and cytochrome c release. 
The pathway of Bortezomib-induced apoptosis was investigated by looking at caspase activation. Both caspase-9 and caspase-3, but not caspase-8, were activated after DoHH2 cells were treated with Bortezomib. The activation of caspases was prevented by quercetin (Figure 3 A). This indicates that Bortezomib-mediated apoptosis is via the mitochondrial/caspase-9 pathway. Previously, we have shown that Bortezomib-induced apoptosis was associated with Bax activation, demonstrated by Bax protein accumulation, translocation to mitochondria and a conformational change in Bax.6 Quercetin was also found to up-regulate Bax in tumor cells.25 We tested whether the inhibitory effect of quercetin on Bortezomib is at the mitochondrial level. DoHH2 cells were pre-treated with different concentrations of quercetin (10 to 60 µM) and then incubated with or without 20 nM Bortezomib. At high concentrations, quercetin (60 µM) alone induced a conformational change in Bax. Bortezomib-induced Bax conformational change was completely inhibited by 20 µM quercetin. The inhibitory effect of quercetin on Bortezomib-induced Bax conformational change was also confirmed in primary CLL cells (Figure 3 B). Bax translocation was tested in primary CLL cells by immuno-fluorescence staining. The active Bax was only detected in the Bortezomib-treated cells, as shown by the yellow-orange color produced by overlapping green-stained active Bax and red-stained mitochondria. This was not seen in the control, quercetin treated and quercetin/Bortezomib co-treated CLL cells (Figure 3 C). These results indicate that Bortezomib-induced Bax conformational change and translocation can be blocked by quercetin. 
Cytochrome c release from mitochondria is a crucial event during Bax-dependent apoptosis. Therefore, the effect of Bortezomib-induced Bax activation on the localization of cytochrome c was investigated by immuno-fluorescence staining. In the control, quercetin, or quercetin/Bortezomib treated CLL cells, cytochrome c was detected in the mitochondria: shown by the yellow-orange color produced by overlapping green-stained cytochrome c and red-stained mitochondria. Cytochrome c release from mitochondria was seen in Bortezomib-treated cells, as the green cytochrome c was separated from the red mitochondria (Figure 3D). These results confirmed that Bortezomib-induced Bax activation was accompanied by cytochrome c release and quercetin can block these apoptotic events. 
The inhibitory effect of quercetin on Bortezomib is unrelated to its anti-oxidative property. 
To test whether the inhibitory effect of quercetin on Bortezomib is due to its anti-oxidative function, ROS, m and apoptosis were measured simultaneously by flow cytometry. Bortezomib induced ROS generation, including H2O2 and O2¯, m reduction, and apoptosis in CLL cells. Quercetin alone (at 20 M) did not induce apoptotic events, but it completely inhibited Bortezomib-induced ROS production, decreases in m and apoptosis (Figure 4 A, B, C and D). This could suggest that the inhibitory effect of quercetin on Bortezomib may be caused by blocking ROS generation. However, Bortezomib-induced apoptosis in the transformed HRC57 and the malignant DoHH2 B-cell lines was not associated with ROS production.  Bortezomib induced apoptosis and m reduction, but not ROS production in these two cell lines. However, quercetin was still able to inhibit Bortezomib-induced m collapse and apoptosis (Figure 4 E and F).
	ROS scavengers, but not caspase inhibitors, block all Bortezomib-induced apoptosis in mantle cell lymphoma.26 We therefore tested whether the ROS scavenger N-acetyl-L-cysteine (NAC) could inhibit Bortezomib-induced apoptosis in the DoHH2 cell line and primary CLL cells. Cells were pre-treated with 10 mM NAC26 for 2 hours and then treated with 20 nM Bortezomib for 12 hours. NAC did not show any inhibitory effect on Bortezomib-induced ROS generation, m loss and apoptosis. In fact, the hallmarks of Bortezomib-mediated apoptosis were enhanced in the primary CLL cells (Figure 5). Further increases in NAC were toxic to CLL cells (data not shown). Nevertheless, MG-132-induced ROS production was inhibited by 10 mM NAC (Figure 5 C) and accordingly apoptosis was partly inhibited by NAC (data not shown).  In contrast, quercetin did not show inhibitory effects on MG-132-induced apoptosis in CLL cells (data not shown), suggesting that the inhibitory effect of quercetin on Bortezomib may not be at the proteasome level.
The interaction between quercetin and Bortezomib, MG-262 or Boric acid is associated with their chemical structures. 
We tested whether other dietary flavonoids also have inhibitory effects on Bortezomib.  Quercetin, myricetin, apigenin and kaempferol are all dietary flavonoids which possess proteasome inhibitory and anti-oxidative functions.15, 27,28,29 The inhibitory effect of these flavonoids on Bortezomib-induced apoptosis was tested in the DoHH2 cell line. The maximum non-lethal concentrations of these flavonoids were used for these experiments. According to the published data15, these concentrations were all higher than their IC50 for inhibition of the 26S proteasome. Interestingly, only myricetin showed a significant inhibitory effect on Bortezomib-mediated apoptosis. Similar to quercetin, none of these flavonoids had blocking effects on MG-132-induced apoptosis (Figure 6 A).
	The chemical structures show that there are similarities between quercetin and myricetin. Quercetin is a catechol or pyrocatechol with two hydroxyl groups (-OH) on neighboring carbon atoms of their B-rings; and myricetin, a pyrogallol, has three –OH groups; whereas both apigenin and kaempferol have only one isolated –OH group on the B ring (Figure 6 B). The complex formation in aqueous solution of boron acids with 1,2-dihydroxybenzene (catechol) and its simple derivatives has been well characterized chemically for several decades.30,31 The boronic acid group, -B(OH)2, that is present in Bortezomib can be expected to form cyclic boronate esters with the catechols and pyrogallols groups, but not with flavonoids such as apigenin and kaempferol in which pairs of adjacent hydroxyl groups are absent  (Figure 6 C). The inhibitory effects of plasma on Bortezomib cannot be attributed solely to quercetin as its reported peak serum concentration after a supplemental diet is too low24. Quercetin in the plasma alone could not reach the maximum inhibition on Bortezomib. However, there are many dietary flavonoids which have similar structures with quercetin or myricetin (Table 1), so the intake of dietary flavonoids may reduce the killing activity of Bortezomib on circulating leukemic cells by the formation of a boronate complex. We also confirmed that several other catechols and pyrogallols, such as Epigallocatechin (EGC), Epigallocatechin gallate (EGCG),  Delphinidin, and Cyanidin, all have an inhibitory effect on Bortezomib-induced apoptosis, but other compounds such as curcumin and resveratrol do not have similar effect (data not shown).
The action of quercetin on two other proteasome inhibitors was also studied: MG-262, which has a boronic acid moiety32 and lactacystin, which does not.33 Similar to Bortezomib, MG-262, at concentrations between 10 to 200 nM, showed a strong pro-apoptotic activity on DoHH2 cells. Pre-incubation with 20 M quercetin significantly inhibited MG-262-induced apoptosis (Figure 6D). Lactacystin induced apoptosis in DoHH2 cells was not inhibited by quercetin (Figure 6 E). 
Raman spectroscopy was used to illustrate the chemical reactions between quercetin and Bortezomib, MG262 or boric acid (Figure 6 F). For the chemical reaction between Bortezomib and quercetin, the spectral range of 990-760cm-1 showed considerable differences between the spectra of Bortezomib and that of Bortezomib plus quercetin (Figure 6 F1). Distinct differences are observed in the regions of 950-830cm-1, which are due to C-C and C-O stretching, respectively.34,35,36 The peaks in the area of 820 – 760cm-1 can be attributed to ring vibrations.34,37 The spectral differences clearly indicate that chemical structure is changing (see Figure 6 F) and indicate shifts of peak positioning, which are mainly due to changes in the electronegativity of the molecules and polarizability of the chemical bonds.
The chemical reaction between quercetin and MG-262 was also observed by the differences between the spectra of quercetin and that of MG-262 plus quercetin in the spectral region of 1540-670cm-1 (Figure 6 F2). The differences in the region of ~1400cm-1 can be attributed to C-O cm-1 symmetric stretch.34,39 The shift in the 680cm-1 peak originated from C-C twisting mode. 34,36,38
To further confirm that quercetin reacts with the boronic containing chemicals, the inorganic boric acid was tested. The spectra for quercetin and quercetin plus boric acid show the reaction between the two chemicals (Figures 6 F3 and F4). Figure 6 H shows the spectra changing in the region of 1580-1080cm-1, indicating that the chemical structure is altered. The spectral differences were also observed in the area of 1150-1080cm-1, demonstrating C-C stretching.34,38 In addition, peaks located in the region of 1450-1410cm-1 originate from symmetric stretching vibration of C-O,35 and those in ~1500cm-1 can be assigned to C=C stretching in rings.34 Spectra presented in Figure 6 F4 and Figure 6 F1 illustrated within the same region, indicate that similar changes take place in the reactions between quercetin with Bortezomib and quercetin with boric acid. 
Inorganic boric acid restored the apoptosis-inducing effect of Bortezomib in the presence of quercetin.
The inorganic boric acid, B(OH)3, was used to abolish quercetin-mediated inhibition of Bortezomib by competitively binding to quercetin. Boric acid alone or in combination with quercetin did not induce apoptosis in DoHH2 or CLL cells (Figure 7). Boric acid sensitized DoHH2 cells to killing by Bortezomib (Figure 7 A). Importantly, boric acid effectively prevented quercetin-mediated inhibition of Bortezomib-induced apoptosis in a dose-dependent manner in both DoHH2 and CLL cells (Figure 7 A and B). Finally, it was observed that boric acid can restore the apoptotic effect of Bortezomib when CLL cells were treated with autologous plasma (Figure 7 C). 

Discussion
Bortezomib has shown poor efficacy in the treatment of CLL in vivo, despite potent in vitro activity.7,8  We demonstrate that the apoptotic effect of Bortezomib on CLL can be blocked by the presence of 50% autologous plasma. This indicates the presence of survival factors or active compounds that can inhibit the killing effect of Bortezomib. This inhibitory effect is due to chemical reactions between quercetin and boronic group containing chemicals, but not related to HSA. We found that a flavonoid, quercetin, blocks Bortezomib-induced apoptosis, measured in terms of Bax conformational change and translocation, cytochrome c release, ROS generation, m reduction, caspase activation, externalization of phosphatidylserine (Annexin V assay) and DNA fragmentation. 
	Quercetin is one of the abundant flavonol-type flavonoids, commonly found in vegetables and fruits. The average daily intake of flavonoids (quercetin, myricetin, kaempferol) and two other flavone-type flavonoids (apigenin and luteolin), was estimated to be 23 mg/day, with quercetin (mean intake 16 mg/day) as the most consumed of these five flavonoids.40 Quercetin is rich in the plasma, and is extensively plasma bound, almost exclusively to human serum albumin.12 The molecular interaction between serum albumin and quercetin involves ionic interactions between the negatively charged quercetin and several ionic and polar amino acids at the putative binding site.41 Binding to albumin, quercetin elicits fluorescence. The plasma concentration of quercetin is tightly associated with its dietary intake.42 Therapeutically, it has been used in anti-aging, anti-cancer and anti-inflammatory treatment. Flavonoids, such as quercetin, myricetin, kaempferol, apigenin, also have an inhibitory effect on the chymotrypsin-like activity of 26S and 20S proteasome.15 Using computational modeling, the potential interactions of these flavonoids with the chymotrypsin site (5 subunit) of the proteasome were detected.15 These flavonoids also have apoptosis-inducing effects on cancer cells. 
Quercetin and Bortezomib share similarities with respect to proteasome inhibition and the induction of apoptosis (Table 2). They both can be used in the treatment of cancer. However, the differences between these two compounds are (1) Bortezomib is a boronic dipeptide acid and quercetin is a flavonoid; (2) Bortezomib is a ROS-inducing agent and quercetin is an anti-oxidant. The question is whether they are synergistic or counteract each other in combination. We observed that quercetin prevented Bortezomib-induced ROS generation and apoptosis in primary CLL cells. However, quercetin also blocked Bortezomib-induced apoptosis in B-cell lines in which ROS generation was not evoked. Studies from other groups demonstrated that Bortezomib-induced apoptosis in mantle cell lymphoma cells was caused by ROS generation and could be prevented by 10 mM NAC, a ROS scavenger.26 In our study, 10 mM NAC neither blocked Bortezomib-induced apoptosis in B-cell lines nor in the primary CLL cells. Quercetin induces Bax accumulation and activation at higher doses, which was associated with apoptosis, in good agreement with previous work.15 Quercetin at 20 M concentration - which was not lethal to B-cells - blocked Bortezomib-induced Bax activation, cytochrome c release from mitochondria, caspase-3 and caspase-9 activation, and apoptosis. Moreover, neither quercetin nor Bortezomib mediated caspase-8 activation, implying that Bortezomib-induced apoptosis is via the mitochondrial/caspase-9 pathway.
Proteasome activity in human tumor samples has been measured in parallel with its activity in blood. Bortezomib-mediated proteasome inhibition in prostate and lymph node samples was similar to that in blood. Inhibition of activity in the bone marrow was approximately one half that observed in blood.43 The reasons for this differential activity include differential tissue distribution of Bortezomib, as well as differential susceptibility of cells at different tissue sites. Interestingly, these observations have not been translated to clinical efficacy in CLL, where the effects of Bortezomib used as a single agent are disappointing, but activity was seen at all sites, with a reduction in lymphocytosis, lymphadenopathy and splenomegaly.8 On the other hand, Bortezomib is highly active in myeloma, another B-lymphoid malignancy, suggesting differential sensitivity to Bortezomib according to tumor type. We found that myeloma cell lines did not show increased sensitivity to Bortezomib-induced apoptosis as compared to transformed HRC57 or lymphoma DoHH2 cells. However, while quercetin was able to inhibit Bortezomib-induced apoptosis of primary CLL, HRC57 and DoHH2 cells, this protective effect was diminished for the myeloma cell lines when they were pre-incubated with quercetin. These results suggest that quercetin (at 20 M) has (i) a direct effect on myeloma cells, but not CLL, HRC57 or DoHH2 cells, to increase sensitivity to, and/or synergize with, Bortezomib, which is balanced by (ii) a protective effect from Bortezomib-induced apoptosis, which involves direct interaction with Bortezomib and the formation of boronate complexes. Whether dietary intake of quercetin could alter Bortezomib-mediated killing of cancer cells in patients with leukemia is unknown, but the lowest concentration tested in our study was 10 M, which is 12.5 times higher than measured serum levels (0.8 M) even after supplemental quercetin.24;44 Other dietary flavonoids in both catechol and pyrogallol groups are also able to inhibit Bortezomib activity in vivo, as shown for myricetin in this study and listed compounds in the Table 1. Given the ability of inorganic boric acid to restore the activity of Bortezomib in the presence of quercetin, it would be important to study the effects of both dietary quercetin, other catechols and supplemental boric acid on the susceptibility of cells to Bortezomib mediated killing in vivo and in vitro. It is well known that the toxicity ofIndeed, ingested inorganic boric acid is non toxic – it is even safert than very low to low when eaten, even less than that of table salt – suggesting that . We suggest that a combined application of Bortezomib with and boric acid would have great improvement on the clinical treatment on human leukemiamay have clinical application. 
	Not all dietary flavonoids can inhibit Bortezomib. Myricetin showed a similar effect to quercetin on the inhibition of Bortezomib, but kaempferol and apigenin did not. Quercetin is catechol and myricetin is pyrogallol. Bortezomib is a boronic acid derivative.  A notable feature of the chemistry of both boric and boronic acids is their strong tendency to form complexes with either catechols or pyrogallols.30,31 The efficacy of Bortezomib was tested in the presence of inorganic boric acid. Boric acid sensitized CLL cells to Bortezomib-induced apoptosis in a dose-dependent manner. It also abolished quercetin or serum-mediated inhibition of Bortezomib; this is consistent with competition between boric acid and Bortezomib for binding to quercetin in the plasma. Furthermore, quercetin also interferes with MG-262, another boronic acid-based proteasome inhibitor. Raman spectroscopy revealed the chemical reactions that can take place in the plasma between quercetin and Bortezomib, boric acid, or MG-262. 
This study suggests that the inability of Bortezomib to induce apoptosis in circulating leukemic cells may be partly due to the presence of catechols and pyrogallols in the plasma. Quercetin did not inhibit the apoptotic activity of MG-132, a tripeptidyl aldehyde proteasome inhibitor, or lactacystin, a β-lactone-related proteasome inhibitor. Flavopiridol, a novel anti-cancer drug, is a synthetic flavone but does not contain a catechol structure in the molecule.45 It is a potent chemotherapeutic drug in the treatment of CLL46 and is also able to synergize with Bortezomib in inducing apoptosis of CLL in vitro.47 – this combination could also be of interest clinically, with the lack of a catechol group meaning Flavopiridol would not exert inhibitory binding effects withplus Bortezomib would be a safe combination in the treatment of leukemia.
	In summary, quercetin, a dietary flavonoid, can block the hallmarks of Bortezomib-induced apoptosis in both cell lines and primary CLL cells. However, not all flavonoids or ROS scavengers can inhibit Bortezomib. The inhibitory effect is associated with the catechol and pyrogallol structures of some flavonoids, such as quercetin, cyaniding, myricetin, EGC, EGCG, and delphinidin, and complex formation with the boric acid group in Bortezomib. The differential in vivo activity of Bortezomib seen in myeloma and CLL may partly be attributable to the effect of dietary flavonoids:  quercetin primes myeloma cells, but not CLL cells, such that they become more sensitive to Bortezomib-induced killing. Further work will elucidate the in vivo significance of these findings, which in turn will inform the need for dietary advice on the intake of flavonoids, as well as drug manipulation of flavonoid activity.
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Figure 1. A comparison of Bortezomib-induced apoptosis in culture medium versus autologous plasma.
CLL cells were cultured in the culture medium (A, n=8) or 50% fresh autologous plasma (B, n=5) and incubated with or without 20 nM Bortezomib for 12 hours. Apoptotic cell death was measured by the Annexin V assay with flow cytometry. (*) indicates a statistically significant difference (P<0.001) between treated and control as analyzed by the t-test. (C) Effect of HSA or quercetin on Bortezomib-induced apoptosis. DoHH2 cells were pre-incubated with HSA or HSA plus quercetin for 1 hour at 37C and then treated with 20 nM Bortezomib (Borte) for 16 hours. ‘Control’ indicates HAS alone; ‘Quercetin’, HAS plus quercetin; ‘Borte’, HAS plus Bortezomib; ‘Q+B’, quercetin plus Bortezomib. (D) Dose-dependent fluorescence production was determined after quercetin was mixed with HSA. ‘FI’ indicates fluorescent intensity. Data shown are mean ± SD from three separate experiments. Error bars represent standard deviation.
Figure 2. Inhibitory effect of quercetin on Bortezomib-induced apoptosis. 
(A) Fresh CLL cells (1×106) were pre-treated with quercetin (20-60 µM) for 1 hour and then incubated with (lower panel) or without (upper panel) Bortezomib (20 nM) for 12 hours. Apoptotic cell death was measured by the DNA content assay using flow cytometry. The percentage of cells in the gate M1 indicates apoptotic or sub- G0/G1 cells.  The flow cytometry profiles shown are one typical experiment from over ten CLL samples. (B) The inhibitory effect of different concentrations of quercetin on Bortezomib (20 nM)-induced apoptosis on the EBV transformed HRC57, DLBCL DoHH2 and myeloma cell lines, U266 and RPMI-8226. (C) The inhibitory effect of quercetin (20 M) on different concentrations of Bortezomib. ‘Q’ and ‘B’ represent quercetin and Bortezomib, respectively. ‘Q+B’ means that quercetin was added one hour prior to Bortezomib and ‘B+Q’ indicates that they were added together. (*) indicates a statistically significant inhibitory effect of quercetin on Bortezomib as analyzed by ANOVA (P<0.0001). Data shown are mean ± SD from three separate experiments.
Figure 3. Quercetin blocks Bortezomib-induced Bax activation and cytochrome c release.
Cells were pre-treated with 20 M of quercetin and then incubated with or without 20 nM Bortezomib for 12 hours. (A) Caspase activation. DoHH2 cells were used for caspase activity assay, as described in the methods.  (*) indicates a statistically significantly increased activity of caspase as analyzed by t-test (P<0.0001). Data shown are mean ± SD from three separate experiments. (B) Bax conformational change was determined in DoHH2 (the left panel) and primary CLL cells (the right panel) by immuno-precipitation. DoHH2 cells were treated with different concentrations of quercetin, with or without 20 nM Bortezomib. The clone 6A7 anti-Bax antibody was used for the immuno-precipitation and the clone 2D2 Bax antibody was used for Western blotting. The active Bax indicates the conformationally changed form of Bax. Western blotting for -actin represents an equal loading of proteins. Bax translocation (C) and cytochrome release from mitochondria (D) were assessed by immuno-staining in CLL cells. Mitochondria were stained with Mito-TrackerTM red CMRos showing a red color. Bax was stained with the conformation-specific clone 3 Bax antibody (C) and cytochrome c was stained with cytochrome c antibody (clone 6H2.B4) (D). Slides were then co-stained with FITC-conjugated anti-mouse antibody (green color). Finally, the nucleus was stained with DAPI (blue). The pictures in the top panel (C) show that cells were stained with Mito-Tracker red and Bax, and those in the bottom panel present cells with merged DAPI staining. Arrows in (D) indicate released cytochrome c in the apoptotic cells. ‘Q’ and ‘B’ represent quercetin and Bortezomib, respectively.

Figure  4. Effect of quercetin on Bortezomib-induced oxidative and apoptotic events.
Fresh primary CLL cells (106/ml) were pre-treated with 20 M quercetin for one hour and then incubated with 20 nM Bortezmib for 12 hours. Cells were washed twice with HBSS. For the measurement of ROS (A), cells were stained with both 40 M HE (O2¯) and 5 M H2DCF-DA (H2O2) at 37C for 30 minutes. ROS production was measured by flow cytometry in the FL1-H and FL3-H channels. For the determination of m (B), cells were incubated with 20 nM TMRM at 37C for 15 minutes and m was measured in the FL3-H channel. For the Annexin V assay (C), cells were resuspended in the binding buffer and then stained with Annexin V-FITC and PI at room temperature for 15 minutes. Apoptotic cells were analyzed in both the FL1-H and FL3-H channels. Annexin V+/PI- and Annexin V+/PI+ cells were counted as apoptotic. The number in each chart indicates that the percentage of cells that underwent apoptosis. (D-F) Statistical data from 5 CLL patients (D), the HRC57 cell line (E) and the DoHH2 cell line (F). Statistical significance of the inhibition of quercetin upon Bortezomib was analyzed by the t-test. * indicates P<0.001. 
Figure 5. Effect of NAC on Bortezomib-induced apoptosis. 
CLL cells were pre-treated with 10 mM NAC for 2 hours and then incubated with 20 nM Bortezmib or 1 M MG-132 for 12 hours. m (A), Annexin V (B) and ROS (C) were determined by flow cytometry. The conditions for the experiment were similar to those described in the Figure 4.
Figure  6. Potential complex formation of Bortezomib with catechols.
(A) Effect of flavonoids on Bortezomib-induced apoptosis. DoHH2 cells were pre-treated with 30 M myricetin, 20 M kaempferol or 5 M apigenin individually for 1 hour and then incubated with or without 20 nM Bortezomib or 1 M MG-132 for 12 hours. Apoptosis was measured by the Annexin V assay. Data shown (mean ± SD) were from three separate experiments. Inhibition of myricetin on Bortezomib-induced apoptosis was statistically analyzed by the t-test, *P<0.001. (B) Chemical structures of quercetin, myricetin, kaempferol and apigenin. The B-rings of quercetin and myricetin are substituted catechols. (C) Chemical structure of Bortezomib (C1), MG-262 or MG-132 (C2), and complex formation of catechol derivatives with boronic acids to form boronate esters (C3). (D) Inhibitory effect of quercetin on MG-262-induced apoptosis. DoHH2 cells were pre-incubated with or without 20 M quercetin for 1 hour and then treated with MG-262 for 12 hours. ‘*’ indicates significant inhibition as analyzed by ANOVA (P<0.0001). (E) Effect of quercetin on lactacystin-induced apoptosis. DoHH2 cells were pre-incubated with 20 M quercetin for 1 hour and then treated with lactacystin for 12 hours. Apoptosis was determined by DNA content assay with flow cytometry. Data shown (mean ± SD) were from three separate experiments. (F) Detection of chemical reactions by Raman spectroscopy. Chemical reactions between quercetin and Bortezomib (F1), quercetin and MG-262 (F2), and quercetin and boric acid (F3 and 4). Boxes indicate significantly altered spectra. 
Figure 7. Effect of boric acid in Bortezomib-induced apoptosis.
DoHH2 (A) or CLL (B and C) cells were pre-treated in various concentrations of boric acid or 2 hours and then treated with 20 nM Bortezomib with or without 20 M quercetin for 16 hours. Cells were suspended in the culture medium (A and B) or 50% autologous plasma (C). ‘BA’, ‘Q’, and ‘B’ indicate boric acid, quercetin and Bortezomib, respectively. Data shown (mean ± SD) were from five separate experiments and the error bars have been omitted for clarity. 

Table 1. Dietary flavonoids with catechol and pyrogallol structures.
Catechols or Pyrocatechols	Nature source	Pyrogallols	Nature source
Quercetin 	Fruits, vegetables, green tea, red wine	Myricetin	fruits, vegetables and herbs
Catechin  	Green tea	Gallic acid	tea
Epicatechin (EC)	Green tea	Gallocatechin (GC)	Green tea
Epicatechin gallate (ECG)	Green tea	Epigallocatechin (EGC)	Green tea
Caffeic acid 	Coffee, fruits, vegetables and herbs 	Epicatechin gallate (ECG)	Green tea
Rutin	Buckwheat	Epigallocatechin gallate (EGCG)	Green tea
Luteolin	Fruits, vegetables	Tannin 	Tea, wine, fruits, and chocolates 
Cyanidin	Color of fruits	Delphinidin 	Color of fruits

Table 2. Comparison of apoptosis-inducing effects of quercetin and Bortezomib.
Property	Quercetin	Bortezomib	References
Compound	Flavonoid	Boronic dipeptide 	1, 12





Cell cycle	G2/M arrest	G2/M arrest	50, 51
Proliferation	Inhibition	Inhibition	50, 51
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